Frequency Therapeutics has raised $62 million to take its Astellas-partnered hearing loss drug into phase 2a. The series C is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,